AAA_Algernon QT - pending

Source: Streetwise Reports (1/20/22)

Belgium Firm to Buy Epilepsy-Focused Biopharma Co. for $1.9B
(01/19/2022)

Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met.

Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.

This Pharmaceutical Company Has a Brilliant Concept
Source: PennyQueen (01/17/2022)

Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.

Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial
Source: Streetwise Reports (01/12/2022)

Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study.

Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.